JPMorgan Chase & Co’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $564K | Buy |
87,989
+33,920
| +63% | +$217K | ﹤0.01% | 4010 |
|
|
2025
Q1 | $191K | Sell |
54,069
-1,537
| -3% | -$5.44K | ﹤0.01% | 4456 |
|
|
2024
Q4 | $210K | Sell |
55,606
-84,953
| -60% | -$321K | ﹤0.01% | 4512 |
|
|
2024
Q3 | $455K | Buy |
140,559
+83,048
| +144% | +$269K | ﹤0.01% | 4068 |
|
|
2024
Q2 | $109K | Sell |
57,511
-352,248
| -86% | -$669K | ﹤0.01% | 4554 |
|
|
2024
Q1 | $1.16M | Buy |
409,759
+337,871
| +470% | +$960K | ﹤0.01% | 3475 |
|
|
2023
Q4 | $1.06M | Sell |
71,888
-19,077
| -21% | -$281K | ﹤0.01% | 3500 |
|
|
2023
Q3 | $1.67M | Sell |
90,965
-99,331
| -52% | -$1.82M | ﹤0.01% | 3105 |
|
|
2023
Q2 | $4.1M | Buy |
190,296
+88,596
| +87% | +$1.91M | ﹤0.01% | 2627 |
|
|
2023
Q1 | $2.98M | Buy |
101,700
+51,999
| +105% | +$1.53M | ﹤0.01% | 2791 |
|
|
2022
Q4 | $1.84M | Buy |
49,701
+30,437
| +158% | +$1.12M | ﹤0.01% | 3017 |
|
|
2022
Q3 | $542K | Buy |
19,264
+13,132
| +214% | +$369K | ﹤0.01% | 3695 |
|
|
2022
Q2 | $118K | Buy |
6,132
+1,635
| +36% | +$31.5K | ﹤0.01% | 4565 |
|
|
2022
Q1 | $58K | Buy |
+4,497
| New | +$58K | ﹤0.01% | 4956 |
|